Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Elevar Therapeutics
Manufacturing
Inside the FDA concerns that sank Hengrui's PD-1 drug filing
The breadth of problems uncovered by the FDA is surprising considering the plant has been producing camrelizumab for the Chinese market since 2019.
Angus Liu
Jul 16, 2024 4:50pm
Eisai, Takeda, BIOSECURE—Fierce Pharma Asia
Jul 12, 2024 9:05am
UPDATED: Elevar, Hengrui eye accelerated refile for PD-1 combo
Jul 12, 2024 12:08am
ASCO: Bristol calls Roche and AZ's bets in 1L liver cancer
Jun 4, 2024 8:00am
AstraZeneca, Hengrui, Takeda—Fierce Pharma Asia
May 24, 2024 8:31am
FDA rejects Elevar, Hengrui's PD-1 combo
May 17, 2024 10:16am
